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ADHD medications only during the school year and stop treat-
ment in the summer months. Assuming that a child meets the
DSM-IV-TR criteria for ADHD, taking him/her off treatment,
even outside the school setting, could impair his/her ability to
function in everyday life. At the same time, it provides the child
with a holiday from potentially serious side effects associated
with stimulant use. Further research is needed to compare these
and other beneﬁts/risks associated with discontinuing ADHD
therapy during the summer months.
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OBJECTIVE: To assess the impact of prior medication use and
comorbidities on treatment initiation with duloxetine vs. ven-
lafaxine XR for patients with major depression disorder (MDD)
using retrospective claims data. METHODS: Using the PharMet-
rics Database, we studied commercially insured individuals aged
18–64 who initiated treatment with duloxetine or venlafaxine
XR between July 2005 and July 2006, and had 1 prior diag-
nosis with MDD and continuous enrollment during 12 months
prior to initiation date. Initiation was deﬁned as the ﬁrst use of a
medication preceded by three months without a prescription of
the same medication. Chi-square and Logistic regression analysis
of patients’ demographics, past-year medication use and comor-
bidities assessed predictors of initiations with duloxetine vs.
venlafaxine XR. RESULTS: A total of 12,662 patients (73.8%
female) initiated treatment with duloxetine, and 14,801 (72.1%
female) with venlafaxine XR. Compared to venlafaxine XR
patients, signiﬁcantly more duloxetine patients received 3
unique antidepressants (39.5% vs. 25.2%), 3 unique pain
medications (25.8% vs. 15.1%), SSRIs (55.5% vs. 41.2%),
TCAs (12.5% vs. 7.5%), analgesics (63.6% vs. 51.6%), anticon-
vulsants (31.3% vs. 19.2%), or hypnotics (31.5% vs. 22.0%),
and had 8 unique co-morbid medical conditions (38.8% vs.
29.5%) and diagnoses with pain (76.4% vs. 67.1%) (all p-values
<0.001). Regression results revealed that the signiﬁcant factors
for duloxetine initiation vs. venlafaxine XR were prior use of 3
unique antidepressants (OR = 1.34), 3 unique pain medi-
cations (OR = 1.24), SSRIs (OR = 1.51), TCAs (OR = 1.19),
analgesics (OR = 1.12), anticonvulsants (OR = 1.45), hypno-
tics (OR = 1.25), and prior medical comorbidities of pain
(OR = 1.11) (all p-values <0.001). CONCLUSION: The results
suggest that duloxetine patients with MDD are more likely to
have more medical conditions and complex prior medication
treatments than venlafaxine XR patients.
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OBJECTIVE: This study examined the health service utilization
and treatment costs among depression patients who received
antidepressant medication, psychotherapy or both. METHODS:
This study used medical and pharmacy claims data from 220,620
employees from three employer groups from September 2002 to
December 2003. Depression patients (n = 4653) were identiﬁed
using ICD-9 diagnosis codes from medical claims data. Differ-
ences in treatment costs and comorbid conditions were examined
between depression patients who received psychotherapy and
those who did not. RESULTS: Among eligible members, 4,653
(2.1%) had a primary diagnosis of depression. Nearly 70% were
female with an average age of 39.7 years. Approximately half of
the depression patients (46.9%) received antidepressant medica-
tion alone while 34.2% of patients received both psychotherapy
and medication. Only 19.3% of depression patients received
psychotherapy without medications. The average total treatment
cost for depression patients who received both psychotherapy
and medications was $10,565, while the average treatment cost
for patients who only used medication was $10,014. These treat-
ment costs were not signiﬁcantly different. The average treatment
cost for psychotherapy alone was $3,945. The most frequent
comorbid conditions among depression patients were muscu-
loskeletal and chronic pain (29.9%), anxiety (26.6%), injuries
(18.7%), hypertension (14.4%), asthma (6.5%), diabetes
(6.1%), arthritis (5.4%), urinary tract infection (4.4%) and drug
dependence and alcohol abuse (4.1%). Depression patients who
received both medication and psychotherapy had signiﬁcantly
more comorbid anxiety (33.1%) and drug and alcohol abuse
(5.8%) than those who received medications or psychotherapy
alone (p < 0.001). CONCLUSION: Depression patients who
used psychotherapy including antidepressant medications did
not have signiﬁcantly different health care costs than depression
patients who did not receive psychotherapy treatments. Depres-
sion patients with comorbid psychological conditions such as
anxiety or drug abuse were more likely to receive psychotherapy
treatment (p < 0.001).
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OBJECTIVE: Those with BPD often present when depressed
leading to potential misdiagnosed and treatment as depression,
particularly in primary care. Inappropriate treatment increases
risk for suicide and rapid cycling. STABLE was initiated to
develop and ﬁeld test evidence-based clinical performance mea-
sures (PM) for endorsment by the National Quality Forum, and
eventual implementation for quality improvement. METHODS:
An expert panel used a validated method to develop 15 perfor-
mance measures for BPD and depression. Field testing was
conducted on 802 medical records among 80 practices (48 psy-
chiatry, 32 primary care) in 28 states. Feasibility was evaluated
using standard parameters with inter-rater reliability evaluated
in a subset of records (proportion agreement and kappa).
RESULTS: Fifteen measures were developed and validated in
four domains: initial assessment, appropriate pharmacotherapy,
adjunctive treatment, monitoring treatment response and
antipsychotic-related metabolic changes. A total of 802 cases
(419 BPD; 383 depression) were audited. In those with depres-
sive symptoms, primary care and specialists assessed patients
for mania or family history of mental health disorders in only
47.6% and 40.8%, respectively. Suicide risk assessment was
only conducted in 71.5% of patients, and substance abuse
assessment in only 60.5%. For BPD speciﬁc measures, results
indicated adequate assessment of functional status at baseline
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